Lung Cancer

stage 4 lung cancer recurrence rate :: Article Creator Genetic Information May Predict Recurrence In Lung Cancer New research revealed that genetic information near healthy tissue surrounding lung tumors may have a better change of determining recurrence in patients with lung cancer. Analyzing the cells around lung cancer tumors may provide a better prediction of lung cancer prediction than analyzation of the tumor itself. Analyzing genetic information and data from healthy tissue near lung tumors could be a more precise tool to predict cancer recurrence post-treatment than analyzing the actual tumors in patients with lung cancer, according to research conducted at by NYU Langone Health and it's Perlmutter Cancer Center. The study focuses on lung adenocarcinoma, which is a type of lung cancer that starts in alveolar epithelial cells. Lung adenocarcinoma represents about one-third of all lung cancer cases within the United States,...

national jewish pulmonary doctors :: Article Creator National Jewish Health Doctors Identify Health Disparities For Indigenous Coal Miners With Black Lung Disease Researchers at National Jewish Health found that Indigenous coal miners may develop disabling black lung disease but are less likely to qualify for medical benefits using currently required lung function standards rather than standards specific to Indigenous populations.  Black lung (also called coal worker's pneumoconiosis) is a debilitating respiratory illness that can occur several decades after a miner's first exposure to coal mine dust. Disease severity can be influenced by adequacy of dust controls, medical surveillance programs for early disease detection, choice of lung function standards to define "abnormal," and other risk factors such as tobacco smoking. Because Indigenous populations face numerous health disparities, researchers also wanted to assess if they...

stage 4 colon cancer with kras mutation :: Article Creator AstraZeneca Joins KRAS Push In Cancer With Chinese Deal AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the KRASG12D mutation and is currently still in preclinical development. AZ has taken an exclusive worldwide license to the drug in a deal that also includes up to $395 million in development and commercial milestone payments, as well as royalties on future sales. If it makes it through to market, UA022 would follow in the footsteps of pioneering KRAS inhibitors Amgen's Lumakras (sotorasib) and Mirati's Krazati (adagrasib), which have been approved as second-line therapies for KRAS-mutated non-small cell lung cancer (NSCLC), but target KRAS G12C, a different mutation. KRAS G12C is the most common form of KRAS mutation in lung cancer, while G1...

lung carcinoid tumor :: Article Creator AI Identifies Non-smokers At High Risk For Lung Cancer Using a routine chest X-ray image, an artificial intelligence (AI) tool can identify non-smokers who are at high risk for lung cancer, according to a study being presented next week at the annual meeting of the Radiological Society of North America (RSNA). Lung cancer is the most common cause of cancer death. The American Cancer Society estimates about 238,340 new cases of lung cancer in the United States this year and 127,070 lung cancer deaths. Approximately 10–20% of lung cancers occur in "never-smokers"—people who have never smoked cigarettes or smoked fewer than 100 cigarettes in their lifetime. The United States Preventive Services Task Force (USPSTF) currently recommends lung cancer screening with low-dose CT for adults between the ages of 50 and 80 who have at least a 20-pack-year smoking history and currently smoke or have quit w...

prognosis for stage 3 non small cell lung cancer :: Article Creator Lung Cancer News From 2023 CURE® highlights some of the most significant lung cancer news of 2023 in honor of Lung Cancer Awareness Month. In honor of November being Lung Cancer Awareness Month, here is a look back at some of the most impactful developments in the space from 2023. Approval of Braftovi with Mektovi Adds to Targeted Options for Metastatic NSCLC The Food and Drug Administration (FDA) recently approved Braftovi (encorafenib) with the combination of Mektovi (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). This FDA approval became the latest development as a targeted therapy to treat patients with lung cancer. "It's just one more in a series of approvals of targeted therapies in lung cancer, which is a story that dates back now for about 15 years (which) is when this originally started," Dr. Gene G...

penile carcinoma in situ :: Article Creator Signs And Symptoms Of Penile Cancer Penile cancer is a type of cancer that begins on or in the penis, an external male sex organ. The penis is also part of the urinary system and is made up of skin, smooth muscle, nerves, and blood vessels. The main part of the penis is called the shaft, and the tip is called the glans.  Penile cancer is rare in North America and Europe. There are about 2,050 new cases diagnosed in the United States each year.  The most common symptom of penile cancer is a change in the skin. You may notice a bump, open sore, or area of thickened skin on the penis. Other symptoms may include swelling, changes in color, and discharge.  The most common symptoms of penile cancer involve skin changes. It is important to remember that most skin changes on the penis are caused by less serious conditions such as an infection.  The first sign of penile cancer is usually a change...

metastatic prostate cancer gleason score 10 life expectancy :: Article Creator Prostate Cancer Is More Likely In Black Men Than In White Men With The Same PSA Levels While it's well established that Black men in the United States are more likely to develop prostate cancer and die of it than white men, a new study shows that Black males are also more likely to have prostate cancer at any PSA level. Prostate-specific antigen (PSA) is a protein made by the prostate (a male sex gland), and levels can be higher in the blood of men who develop prostate cancer. This latest research indicates that Black men may face an increased risk of prostate cancer even at lower PSA levels than white men. "We know Black men are at higher risk, but our study puts a number to that in terms of PSA value," says Julie Lynch, PhD, RN, an author of the study and the director of the precision medicine research team for VA Informatics and Computing Infrastructu...